Roche cements Btk turnaround story in multiple sclerosis: Clinical Report

In a busy week for clinical readouts, Roche stood out for producing the strongest data to date from a Btk inhibitor in multiple sclerosis, while Massachusetts-based biotech Cogent Biosciences saw its market cap approach $5 billion on the back of c-KIT data in gastrointestinal stromal tumors.

Roche (SIX:ROG; OTCQB:RHHBY) said its Btk inhibitor fenebrutinib met the primary endpoints in two Phase III trials in different MS settings. The pharma is already the market leader in both indications...